BioWorld MedTech

Dec. 8, 2016

View Archived Issues

Abbott ready to bolt on Alere based on 'damaging business developments'

After nearly 10 months of waffling on a $5.8 billion decision, Abbott Laboratories might have spotted an emergency exit from its contract to buy Alere Inc. Read More

MIT team reduces beta amyloid plaques in mice using light therapy

Read More

Cures Act sails through Senate in 94-5 landslide

Read More

AdvaMed's Trunzo says least burdensome standard revived

Read More

EU sliding toward a compliance cliff as regulations advance

Read More

Attorney says outcome of hearing on CRISPR patents tough to predict

Read More

Abiomed Impella CP gets green light for high-risk PCI treatment

Read More

Appointments and advancements

Read More

Product briefs

Read More

Financings

Read More

Other news to note

Read More

MDD's Orthopedics Extra

Read More